PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIAL
HIGHLIGHTS * A confirmed pathological complete response has been recorded in the ACCENT trial * A pathological complete response (pCR) is extremely rare in patients undergoing treatment for advanced pancreatic cancer * A pCR means that there are no signs of cancer in tissue examined by a p...
FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US
HIGHLIGHTS * The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in theUSA * The proposed trial would explore the combination of narmafotinib and FOLFIRINOX in advanced pancreatic cancer patients in theUSA MELBOURNE, Australia ,Jan. ...
AACR OVARIAN CANCER CONFERENCE PRESENTATION
HIGHLIGHTS * Data from preclinical studies in ovarian cancer presented at premier international conference inBoston, USA. * Results indicate that Amplia's proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade ser...
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
HIGHLIGHTS * Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer * FOLFIRINOX is the most widely used treatment for pancreatic cancer patients in the US,Canada and most European countries * T...
